𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisapride treatment of constipation in parkinson's disease

✍ Scribed by Dr. W. H. Jost; K. Schimrigk

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
645 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Constipation, a frequent symptom in Parkinson's disease (PD), is probably caused by degeneration of the autonomic nervous system, particularly the myenteric plexus. Cisapride is a drug that causes increased release of acetylcholine in the myenteric plexus. In a pilot study, cisapride therapy was investigated in 20 PD patients, 10 women and 10 men, who suffered from delayed intestinal transit. In all cases, cisapride therapy was associated with a significant acceleration of colonic transit, as measured by radioopaque pellets viewed on radiographs. Pellet count fell from a mean of 53.8 pretreatment to 30.4 after cisapride treatment. No adverse reaction and no β€œovershoot effects,” such as diarrhea, were seen. Our findings suggest that cisapride may alleviate the constipation associated with Parkinson's disease.

πŸ“œ SIMILAR VOLUMES

Tegaserod (Zelnorm) for the treatment of
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
✍ Kelly L. Sullivan; Joseph F. Staffetti; Robert A. Hauser; Peter B. Dunne; Theres πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 45 KB πŸ‘ 1 views

## Abstract We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with b

Long-term results with cisapride in Park
Long-term results with cisapride in Parkinson's disease
✍ Dr. med. Wolfgang H. Jost; Klaus Schimrigk πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 220 KB

## Abstract In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the f

Macrogol for the treatment of constipati
Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study
✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

Severe constipation in parkinson's disea
Severe constipation in parkinson's disease relieved by botulinum toxin
✍ Dr. Alberto Albanese; Giorgio Maria; Anna Rita Bentivoglio; Giuseppe Brisinda; E πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 444 KB

## Abstract A parkinsonian patient with severe outlet‐type constipation was treated with injection of botulinum toxin into the puborectalis muscle. A total of 30 units (Botox) was injected in two sites. Resting anal pressure, maximum voluntary contraction, and pressure on straining were evaluated b

Excess burden of constipation in Parkins
Excess burden of constipation in Parkinson's disease: A pilot study
✍ Julie Kaye; Heather Gage; Alan Kimber; Lesley Storey; Patrick Trend πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 1 views

An analysis was undertaken of clinic-based questionnaires that asked people with Parkinson's disease and a control group of older people without a known neurological condition about their experiences of constipation. People with Parkinson's disease report higher constipation on a validated objective